HCLTech Delivers Robust Performance in Q2FY26 with Revenue Growth of 4.6%
Deal wins at $2.6B; Advanced AI revenue crosses $100m
HCLTech, a leading global technology company, reported 4.6% YOY revenue growth in constant currency (CC) for the quarter ended September 30, 2025. USD revenue was at $3.6 billion, up 5.8% YoY. The company revised its Services Revenue growth (CC) guidance to 4%-5%, while retaining the overall revenue and margin guidance for FY26.
“We had a standout quarter on every front — marked by strong execution, growing demand for our AI-powered solutions and Advanced AI revenue exceeding $100 million this quarter. Our AI strategy is no longer just a vision; it is now a measurable driver of growth, differentiation and innovation. We are transitioning into an AI monetization phase. For the first time, our new bookings surpassed $2.5 billion, without reliance on any mega deal,” said C Vijayakumar, CEO & Managing Director, HCLTech.
HCLTech’s Services revenue grew by 5.5% YoY (CC). Digital revenue was up 15% YoY (CC) and now accounts for 42% of Services revenue. HCLSoftware’s Annual Recurring Revenue, at $1.06 billion, continues to grow.
Industry vertical growth was led by Technology and Services at 13.9% YoY growth (CC), followed by Telecommunications, Media, Publishing and Entertainment at 11.7% YoY (CC) and Financial Services at 11.4% YoY (CC). In terms of geographies, Europe grew at 7.6% YoY (CC) while the Rest of the World grew the fastest at 17.9% YoY (CC). The U.S. grew by 2.4%.
The company announced a dividend of ₹12 per share for the quarter, marking the 91st consecutive quarter of dividend payouts.
“HCLTech delivered strong INR revenue growth of 5.2% QoQ and 10.7% YoY in Q2 FY26. This superior revenue growth is accompanied by enhanced profitability and solid cash generation, with the last twelve months (LTM) FCF/NI ratio at 125%. We remain committed to improving our capital efficiency and are pleased to report LTM ROIC for the company is 38.6%, up 290 bps YoY and for Services business is 45.3%, up 180 bps YoY,” added Shiv Walia, Chief Financial Officer, HCLTech.
The company added 5,196 freshers during the quarter, taking the H1 fresher addition to 7,180. The LTM attrition moderated to 12.6%, among the lowest in the industry.
Key deal wins:
- A leading US-based vacation ownership and resort management company expanded its partnership with HCLTech to modernize and transform its finance, accounting and mortgage operations with AI-powered digital solutions.
- A US-based global consumer goods major selected HCLTech as its strategic partner to manage a large portfolio of enterprise applications and infrastructure across commercial, supply chain and corporate functions.
- A Europe-based global retail major selected HCLTech to modernize its multi-channel application landscape. HCLTech’s solution will leverage AI Force to deliver a digital-first, future-ready platform that will enable seamless customer experiences across online and in-store channels.
Key AI deal wins:
- A UK-based financial services major selected HCLTech to modernize its digital banking platforms and boost productivity. The solution uses AI Force to automate and augment the software development lifecycle, enabling faster time-to-market, improved platform resilience and superior digital experiences for its users.
- A public sector transport authority in Australia selected HCLTech to enhance safety and compliance across waterways using a computer vision-based Physical AI solution. Built on HCLTech AI Foundry, the solution enables real-time detection of congestion, unsafe behavior and hazards at boat ramps, reducing response times and preventing accidents.
- A US-based global manufacturer selected HCLTech AI Advisory services to build an Enterprise AI and Governance framework to scale AI initiatives with measurable ROI, regulatory compliance and Responsible AI principles.
- A leading US-based telecom company selected HCLTech to launch an NVIDIA-powered Emerging Tech AI Lab. HCLTech is delivering advanced Cognitive Infrastructure Services, setting up a high-performance AI cluster and deploying state-of-the-art models such as Llama 405B, Maverick and Scout. This scalable, future-ready platform enables rapid AI experimentation and enterprise-wide AI adoption, reducing time-to-market and driving transformation.
HCLTech received dual recognition from TIME magazine: Highest-ranked India-headquartered technology company for the second consecutive year in the World’s Best Companies 2025 list and ranked among the top 15 in Professional Services in the World’s Most Sustainable Companies 2025 list.
About HCLTech
HCLTech is a global technology company, home to more than 226,600 people across 60 countries, delivering industry-leading capabilities centered around AI, digital, engineering, cloud and software, powered by a broad portfolio of technology services and products. We work with clients across all major verticals, providing industry solutions for Financial Services, Manufacturing, Life Sciences and Healthcare, High Tech, Semiconductor, Telecom and Media, Retail and CPG, Mobility and Public Services. Consolidated revenues as of 12 months ending September 2025 totaled $14.2 billion. To learn how we can supercharge progress for you, visit hcltech.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251013228975/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom